MetaCap

Corbus Pharmaceuticals (CRBP) vs Spero Therapeutics (SPRO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Spero Therapeutics (SPRO) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, losing 67.9% versus a loss of 82.8%. Over five years, CRBP leads with a -92.2% price change compared with -95.1% for SPRO. Spero Therapeutics is the larger company by market cap ($43.2 million vs $42.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRBP-82.85%SPRO-67.88%
+35%-27%-88%
Nov 21, 20251 yearNov 20, 2026
CRBP-92.63%SPRO-95.50%
+130%+11%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRBP versus SPRO key metrics
MetricCRBPSPRO
Share price$2.06$0.742
Market cap$42.45M$43.23M
1-day change-15.40%-10.20%
YTD return-74.69%-68.15%
1-year return-82.85%-67.88%
5-year return-92.23%-95.09%
EPS (TTM)$-6.04$-0.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$66.80M
Revenue growth (YoY)—+39.24%
Net income (latest FY)$-78.54M$8.57M
Operating margin—9.45%
Net margin—12.83%
52-week high$12.88$3.08
52-week low$2.01$0.73
Distance from 52-week high-84.01%-75.91%
Analyst consensusstrong_buynone
Avg. price target upside+1551.94%+573.85%
Average volume1.11M530.46K
Shares outstanding20.61M58.26M
Employees3625
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SPRO has outperformed CRBP by 15.0 percentage points over the past year.

About Corbus Pharmaceuticals

CRBP stock →

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 36 employees

About Spero Therapeutics

SPRO stock →

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

CRBP vs SPRO FAQ

Which is bigger, Corbus Pharmaceuticals or Spero Therapeutics?

Spero Therapeutics (SPRO) is larger, with a market capitalization of $43.23M compared with $42.45M for Corbus Pharmaceuticals (CRBP).

Which stock has performed better over the past year, CRBP or SPRO?

SPRO returned -67.88% over the past 12 months, compared with -82.85% for CRBP (price return, excluding dividends). Past performance does not predict future results.

Are Corbus Pharmaceuticals and Spero Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons